We’re playing a pivotal role in the global movement to stamp out 17 diseases—known as neglected tropical diseases—that together threaten more than a billion people in sub-Saharan Africa, Asia, and Central and South America.
One year after declaring January 30 be annually recognized as National Human African trypanosomiasis (HAT) Day, the Congolese government and PATH celebrate progress toward disease elimination and launch new scholarship fund to train the next cohort of HAT fighters.
November 12-18 is World Antibiotic Awareness Week—a time to raise awareness about the growing threat of drug resistance and our collective responsibility to safeguard the effectiveness of antibiotics through appropriate use. Drug-resistant typhoid is an urgent and growing issue that can be slowed with vaccines, which help prevent illness and the need for antibiotics in the first place. As a principle partner of the Typhoid Vaccine Acceleration Consortium, PATH is helping countries introduce typhoid conjugate vaccines (TCVs) to control outbreaks of typhoid and stem the growth of drug resistance.
Here’s one story from Zimbabwe.
No longer neglected? Japanese encephalitis is a model for new vaccines to prevent other tropical diseases.
New rapid diagnostic tests for onchocerciasis (river blindness) and lymphatic filariasis will guide surveillance of mass drug administration programs needed for elimination.
On the way to vaccinating 300 million children, PATH forged partnerships from local to global levels to ensure the successful and sustainable launch of Japanese encephalitis vaccine.
The Democratic Republic of the Congo’s fight to do away with sleeping sickness is picking up speed, with help from PATH, partners, and a dedicated minister of health.